The effect of bevacizumab (Avastin) treatment on epistaxis in hereditary hemorrhagic telangiectasia

Laryngoscope

Volumn 119, Issue 5, 2009, Pages 988-992

  Simonds, Jana ^a   Miller, Frank ^b   Mandel, Jess ^a   Davidson, Terence M ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Avastin; Bevacizumab; Epistaxis; Hereditary hemorrhagic telangiectasia

Indexed keywords

BEVACIZUMAB; IRON; POTASSIU TITANYL PHOSPHATE; POTASSIUM DERIVATIVE; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD TRANSFUSION; CAUTERIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; EMERGENCY CARE; EPISTAXIS; FEMALE; HUMAN; IRON THERAPY; LASER SURGERY; LOW LEVEL LASER THERAPY; MALE; PRIORITY JOURNAL; QUALITY OF LIFE; RENDU OSLER WEBER DISEASE; SEX RATIO; SOCIAL LIFE; METHODOLOGY; MIDDLE AGED; PILOT STUDY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; EPISTAXIS; FEMALE; HUMANS; LASER THERAPY; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; TREATMENT OUTCOME;

EID: 66349137361     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20159     Document Type: Article

References (18)

1. Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med 1995; 333: 918-924.
2. Richmon JD, Tian Y., Husseman J., Davidson TM. Use of a sprayed fibrin hemostatic sealant after laser therapy for hereditary hemorrhagic telangiectasia epistaxis. Am J Rhinol 2007; 21:187-191.
3. Harvey RJ, Kanagalingam MA, Lund VJ. The impact of septodermoplasty and potassium-titanyl-phosphate (KTP) laser therapy in the treatment of hereditary hemorrhagic telangiectasia-related epistaxis. Am J Rhinol 2008; 22: 182-187.
4. Lund VJ, Howard DJ. Closure of the nasal cavities in the treatment of refractory hereditary haemorrhagic telangiectasia. J Laryngol Otol 1997; 111:30-33.
5. Sadick H., Riedel F., Nairn R., et al. Patients with hereditary hemorrhagic telangiectasia have increased plasma levels of vascular endothelial growth factor and transforming growth factor-beta 1 as well as high ALKI tissue expression. Haematologica 2005; 90:818-828.
6. Andreoli CM, Miller J. Anti-vascular endothelial growth factor therapy for ocular neovascular disease. Curr Opin Ophthalmol 2007; 18:502-508.
7. Maia OO Jr, Bonanomi MT, Takahashi WY, Nascimento VP, Tahakashi BS. Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia. Am J Ophthalmol 2007; 144:296-299.
8. Charbel IP, Holz FG, Scholl HP. Findings in fluorescein angiography and optical coherence tomography after intravitreal bevacizumab in type 2 idiopathic macular telangiectasia. Ophthalmology 2007; 114:1736-1742.
9. Kim JH, Hwang JM. Intravitreal bevacizumab (Avastin) for treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane. Eye 2007; 21:1431-1433.
10. Lynch SS, Cheng CM. Bevacizumab for neovascular ocular diseases. Ann Pharmacother 2007; 41:614-625.
11. Flieger D., Hainke S., Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006; 85: 631-632.
12. Mansour AM, Mackensen F., Arevalo JF, et al. Intravitreal bevacizumab in inflammatory ocular neovascularization. Am J Ophthalmol 2008; 146:410-416.
13. Bashshur ZF, Haddad ZA, Schakal A., Jaafar RF, Saab M., Noureddin BN. Intravitreal bevacizumab for treatment of neovascular age-related macular degeneration: a oneyear prospective study. Am J Ophthalmol 2008; 145: 249-256.
14. Burkart CM, Grisel JJ, Horn DB. Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope 2008; 118:1539-1549.
15. Ruiz N., Fernandez-Martos C., Romero I., et al. Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol 2007; 104:15448-15453.
16. Fakih MG, Lombardo JC. Bevacizumab-induced nasal septum perforation. Oncologist 2006; 11:85-86.
17. Traina TA, Norton L., Drucker K., Singh B. Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist 2006; 11:1070-1071.
18. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 2006; 355:1409-1412.